PFNX - Pfenex Inc.

NYSE American - NYSE American Delayed Price. Currency in USD
6.24
+0.08 (+1.30%)
At close: 4:00PM EDT

6.24 0.00 (0.00%)
After hours: 5:12PM EDT

Stock chart is not supported by your current browser
Previous Close6.16
Open6.07
Bid0.00 x 1100
Ask0.00 x 1000
Day's Range5.95 - 6.29
52 Week Range3.13 - 7.64
Volume180,249
Avg. Volume171,969
Market Cap196.572M
Beta (3Y Monthly)0.86
PE Ratio (TTM)N/A
EPS (TTM)-1.07
Earnings DateAug 6, 2019 - Aug 12, 2019
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est13.00
Trade prices are not sourced from all markets
  • Hedge Funds Have Never Been This Bullish On Pfenex Inc (PFNX)
    Insider Monkey20 days ago

    Hedge Funds Have Never Been This Bullish On Pfenex Inc (PFNX)

    World-class money managers like Ken Griffin and Barry Rosenstein only invest their wealthy clients' money after undertaking a rigorous examination of any potential stock. They are particularly successful in this regard when it comes to small-cap stocks, which their peerless research gives them a big information advantage on when it comes to judging their worth. […]

  • Pfenex Sees Hammer Chart Pattern: Time to Buy?
    Zacks26 days ago

    Pfenex Sees Hammer Chart Pattern: Time to Buy?

    Pfenex has been struggling lately, but the selling pressure may be coming to an end soon.

  • GlobeNewswirelast month

    Pfenex to Participate at the JMP Securities Life Sciences Conference

    SAN DIEGO, June 05, 2019 -- Pfenex Inc. (NYSE American: PFNX) a clinical-stage development and licensing biotechnology company focused on leveraging its Pfēnex Expression.

  • GlobeNewswire2 months ago

    Pfenex and Alvogen Announce European Medicines Agency Accepts Marketing Authorization Application for PF708

    Pfenex Inc. (NYSE American: PFNX) and Alvogen today announced that the European Medicines Agency (EMA) has accepted the Marketing Authorization Application (MAA) submitted by our partner Alvogen for PF708 (teriparatide).  The product is proposed as a therapeutic equivalent in the treatment of osteoporosis to Forteo®. The product is filed with the EMA as a biosimilar in the treatment of osteoporosis to Forsteo®, which achieved $289 million sales in the E.U. and $1.6 billion in global product sales in 2018.

  • Pfenex Inc. (PFNX) Shares March Higher, Can It Continue?
    Zacks2 months ago

    Pfenex Inc. (PFNX) Shares March Higher, Can It Continue?

    As of late, it has definitely been a great time to be an investor in Pfenex Inc. (PFNX).

  • Pfenex (PFNX) Reports Q1 Loss, Tops Revenue Estimates
    Zacks2 months ago

    Pfenex (PFNX) Reports Q1 Loss, Tops Revenue Estimates

    Pfenex (PFNX) delivered earnings and revenue surprises of 52.00% and 84.05%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?

  • GlobeNewswire2 months ago

    Pfenex Reports First Quarter 2019 Results and Provides Business Update

    SAN DIEGO, May 09, 2019 -- Pfenex Inc. (NYSE American: PFNX) is a clinical-stage development and licensing biotechnology company focused on leveraging its Pfēnex Expression.

  • Pfenex (PFNX) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
    Zacks2 months ago

    Pfenex (PFNX) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release

    Pfenex (PFNX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

  • GlobeNewswire3 months ago

    Pfenex to Announce First Quarter 2019 Financial Results on May 9

    SAN DIEGO, April 25, 2019 -- Pfenex Inc. (NYSE American: PFNX), a clinical-stage development and licensing biotechnology company focused on leveraging its Pfēnex Expression.

  • GlobeNewswire3 months ago

    Pfenex Appoints Dr. Robert Peach to Scientific Advisory Board

    Pfenex Inc. (NYSE American: PFNX), today announced the appointment of Robert Peach, Ph.D. to the Pfenex Scientific Advisory Board. “We are very excited to have Dr. Peach join our Scientific Advisory Board and look forward to his insight and contributions as we leverage our Pfēnex Expression Technology platform to expand our development pipeline,” said Eef Schimmelpennink, Chief Executive Officer of Pfenex. “I am looking forward to working with the innovative team at Pfenex and the rest of the Scientific Advisory Board on their efforts to expand their development pipeline leveraging the Pfēnex Expression Technology platform.

  • GlobeNewswire3 months ago

    Pfenex Announces Successful Expiration of 45 Day Waiting Period Under Hatch-Waxman Act

    Pfenex Inc. (NYSE American: PFNX) a clinical-stage development and licensing biotechnology company focused on leveraging its Pfēnex Expression Technology® to improve protein therapies for unmet patient needs, today announced the expiration of the 45-day period for Eli Lilly & Co. (“Lilly”) to file a lawsuit under the Hatch-Waxman Act and stay the approval of PF708 for 30 months. In addition, Pfenex is developing hematology/oncology products, including PF743, a recombinant crisantaspase, and PF745, a recombinant crisantaspase with half-life extension technology, in collaboration with Jazz Pharmaceuticals.

  • GlobeNewswire4 months ago

    Pfenex to Participate at the William Blair Late-Stage Therapeutics Conference

    SAN DIEGO, March 27, 2019 -- Pfenex Inc. (NYSE American: PFNX), a clinical-stage development and licensing biotechnology company focused on leveraging its Pfēnex Expression.

  • GlobeNewswire4 months ago

    Pfenex to Present at the 18th Annual Needham Healthcare Conference

    SAN DIEGO, March 26, 2019 -- Pfenex Inc. (NYSE American: PFNX) a clinical-stage development and licensing biotechnology company focused on leveraging its Pfēnex Expression.

  • GlobeNewswire4 months ago

    Pfenex to Present at the 29th Annual Oppenheimer & Co. Healthcare Conference

    SAN DIEGO, March 18, 2019 -- Pfenex Inc. (NYSE American: PFNX) a clinical-stage development and licensing biotechnology company focused on leveraging its Pfēnex Expression.

  • GlobeNewswire4 months ago

    Pfenex Appoints Dr. Martin B. Brenner as Chief Scientific Officer

    Pfenex Inc. (NYSE American: PFNX), a clinical-stage development and licensing biotechnology company focused on leveraging its Pfēnex Expression Technology® to improve protein therapies for unmet patient needs, today announced the appointment of Martin B. Brenner, DVM, Ph.D., as its Chief Scientific Officer (CSO), effective immediately. “We are pleased to have Dr. Brenner join the Pfenex team at such an important time in the Company’s history. Martin’s experience identifying active modalities and therapies will make him a valuable new member of our executive team as we look to create value for our shareholders via new pipeline candidates,” said Eef Schimmelpennink, Chief Executive Officer of Pfenex.

  • Will Pfenex Continue to Surge Higher?
    Zacks4 months ago

    Will Pfenex Continue to Surge Higher?

    As of late, it has definitely been a great time to be an investor in Pfenex.

  • Thomson Reuters StreetEvents4 months ago

    Edited Transcript of PFNX earnings conference call or presentation 11-Mar-19 8:30pm GMT

    Q4 2018 Pfenex Inc Earnings Call

  • Pfenex (PFNX) Reports Q4 Loss, Misses Revenue Estimates
    Zacks4 months ago

    Pfenex (PFNX) Reports Q4 Loss, Misses Revenue Estimates

    Pfenex (PFNX) delivered earnings and revenue surprises of 29.03% and -46.64%, respectively, for the quarter ended December 2018. Do the numbers hold clues to what lies ahead for the stock?

  • GlobeNewswire4 months ago

    Pfenex Reports Fourth Quarter and Full Year 2018 Results and Provides Business Update

    We believe PF708 is on track to enter the U.S. market as early as Q4 2019, subject to FDA approval and other factors Several significant milestones across the Company’s.

  • Are Insiders Buying Pfenex Inc. (NYSEMKT:PFNX) Stock?
    Simply Wall St.4 months ago

    Are Insiders Buying Pfenex Inc. (NYSEMKT:PFNX) Stock?

    We've lost count of how many times insiders have accumulated shares in a company that goes on to improve markedly. The flip side of that is that there are moreRead More...

  • GlobeNewswire4 months ago

    Pfenex Licensee Successfully Completes a Phase 3 Study and Enters Registration for Pneumosil®

    Pfenex Inc. (NYSE American: PFNX) today announced that Serum Institute of India Private Limited (SIIPL), has completed a pivotal Phase 3 study for Pneumosil® a 10-valent pneumococcal conjugate vaccine, in which Serum Institute indicates all primary and secondary objectives were met.  Pneumosil contains the recombinant carrier protein CRM197 produced by Serum Institute under a license to the Pfēnex Expression Technology®.  Following review of the Complete Study Report and product dossier by the Drug Controller General of India (DCGI), Serum Institute has received an export license for Pneumosil.

  • GlobeNewswire4 months ago

    Pfenex Announces Appointment of New Board Member, Magda Marquet, Ph.D.

    Pfenex Inc. (NYSE American: PFNX), a clinical-stage development and licensing biotechnology company focused on leveraging its Pfēnex Expression Technology® to improve protein therapies for unmet patient needs, today announced the appointment of Magda Marquet, Ph.D. to its Board of Directors, February 28, 2019. Dr. Marquet was also appointed to serve as a member of the corporate governance and nominating committee. “We are pleased to welcome Dr. Marquet to the Pfenex Board.

  • GlobeNewswire5 months ago

    Pfenex and Alvogen Expand Development and Commercialization Collaboration for PF708, a Therapeutic Equivalent Candidate to Forteo®/Forsteo®, to the EU, MENA, and ROW

    Pfenex Inc. (NYSE American: PFNX) and Alvogen Ltd. today announced entering into agreements expanding their collaboration to develop and commercialize Pfenex’s lead product candidate, PF708, a proprietary teriparatide therapeutic equivalent candidate to Eli Lilly & Company’s Forteo®/Forsteo®, to the EU, to certain countries in Middle East and North Africa (MENA) the ROW territories (the latter defined as all countries outside of the EU, US and MENA, excluding Mainland China, Hong Kong, Singapore, Malaysia and Thailand). This collaboration leverages Alvogen’s established international experience and expertise in regulatory, IP and supply chain activities, as well as its established network of specialty marketing and sales pharmaceutical companies in these regions.

  • GlobeNewswire5 months ago

    Pfenex to Participate at Two Investor Conferences in March

    SAN DIEGO, Feb. 27, 2019 -- Pfenex Inc. (NYSE American: PFNX) a clinical-stage development and licensing biotechnology company focused on leveraging its Pfēnex Expression.